{
    "title": "Blow for GSK boss as pharma giant's blood cancer drug Blenrep fails to beat rival treatments in US tests",
    "url": "https://www.dailymail.co.uk/money/markets/article-11458747/GSK-blood-cancer-drug-Blenrep-fails-beat-rival-treatments-tests.html",
    "date": "2022-11-22",
    "keywords": [
        "drug",
        "gsk",
        "share",
        "fund",
        "executive",
        "emma",
        "cancer",
        "oncology",
        "treatment",
        "access",
        "company",
        "month",
        "world",
        "money",
        "diy",
        "platform",
        "investment",
        "account",
        "fee",
        "setback",
        "walmsleygsk",
        "blood",
        "blenrep",
        "series",
        "business",
        "disappointment",
        "pharma",
        "giant",
        "goal",
        "study",
        "market",
        "approval",
        "food",
        "administration",
        "fda",
        "trial",
        "option",
        "union",
        "health",
        "spokesman",
        "category",
        "area",
        "blow",
        "use",
        "zejula",
        "ao",
        "cup",
        "run",
        "swoop",
        "aveva",
        "hanging",
        "balance",
        "schneider",
        "boss",
        "cybersecurity",
        "firm",
        "darktrace",
        "spent",
        "property",
        "bahamas",
        "founder",
        "article",
        "capital",
        "risk",
        "isa",
        "trade",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing"
    ],
    "category": [
        "money",
        "markets"
    ]
}